Randomized controlled trial of abductor muscle damage in relation to the surgical approach for primary total hip replacement: minimally invasive anterolateral versus standard transgluteal approach

Randomized controlled trial of abductor muscle damage in relation to the surgical approach for primary total hip replacement: minimally invasive anterolateral versus standard transgluteal approach - MRT/Weichteil

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00000152

Enrollment

Registered

2009-07-29

Start date

2006-06-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M16.0 M16.1

Interventions

Group 1: Total Hip Replacement via the minimally inavsive anterolateral approach. Group 2: Total Hip Replacement via the lateral transgluteal approach.

Eligibility

Sex/Gender

All

Age

50 Years to 75 Years

Inclusion criteria

Inclusion criteria: patients with primary hip arthritis, unilateral total hip arthroplasty

Exclusion criteria

Exclusion criteria: incompliance, patients with a heavy muscular disease, patients with a heavy damage of the central or peripheral nervous system

Design outcomes

Primary

Measure	Time frame
Preoperatively: 1. MRI to evaluate the soft tissue (cross sectional area, fatty atrophy, tendon defects, inflammation signs (fluid, bursitis, tendinitis) 3- Months follow-up 1. MRI - Evaluation of the soft tissue 3 months postoperatively 12- Months-follow-up 1. MRI - Evaluation of the soft tissue 12 months postoperatively	—

Secondary

Measure	Time frame
Preoperatively 1. Abduction Test (to measure the hip abduction force) 2. Clinical investigation (age, weight (kg), sex, height (cm)) 3. Clinical scores (Harris Hip, Oxf-12-Hip Score, WOMAC, Satisfaction, Pain) 4. Blood test (to evaluate normal values) Postoperatively 1. Blood test (to measure muscle related enzymes for evaluation of muscle trauma) 3- Months follow-up 1. Clinical investigation (to objectify patients outcome) 2. Clinical scores (Harris Hip, Oxf-12-Hip Score, WOMAC, Satisfaction, Pain) 3. Abduction Test (to measure the hip abduction force) 12- Months follow-up 1. Clinical investigation (to objectify patients outcome) 2. Clinical scores (Harris Hip, Oxf-12-Hip Score, WOMAC, Satisfaction, Pain) 3. Abduction Test (to measure the hip abduction force)	—

Measure

Time frame

Preoperatively 1. Abduction Test (to measure the hip abduction force) 2. Clinical investigation (age, weight (kg), sex, height (cm)) 3. Clinical scores (Harris Hip, Oxf-12-Hip Score, WOMAC, Satisfaction, Pain) 4. Blood test (to evaluate normal values) Postoperatively 1. Blood test (to measure muscle related enzymes for evaluation of muscle trauma) 3- Months follow-up 1. Clinical investigation (to objectify patients outcome) 2. Clinical scores (Harris Hip, Oxf-12-Hip Score, WOMAC, Satisfaction, Pain) 3. Abduction Test (to measure the hip abduction force) 12- Months follow-up 1. Clinical investigation (to objectify patients outcome) 2. Clinical scores (Harris Hip, Oxf-12-Hip Score, WOMAC, Satisfaction, Pain) 3. Abduction Test (to measure the hip abduction force)

—

Countries

Germany

Contacts

Public ContactAnne Zergiebel

Charité Campus Mitte Universitätsmedizin Berlin Centrum für Muskuloskeletale Chirurgie Klinik für Orthopädie Klinik für Unfall-u. Wiederherstellungschirurgie

anne.zergiebel@charite.de+4930/450515235

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026